title: Plasma norepinephrine kinetics, dopamine-beta-hydroxylase, and chromogranin-A, in hypothyroid patients before and following replacement therapy.
abstract: Whether the increased plasma norepinephrine level reported in hypothyroidism is the result of impaired norepinephrine (NE) clearance or increased NE release by nerve terminals is unknown. We, therefore, measured plasma NE levels and clearance in 11 hypothyroid patients before [T4 index, 41.2 +/- 7.7 nmol/L (mean +/- SEM); TSH, 71.4 +/- 23.0 mU/L] and 4 +/- 0.5 months after thyroid replacement (T4 index, 136.4 +/- 24.4 nmol/L; TSH, 3.2 +/- 1.2 mU/L) and in 8 healthy volunteers. Plasma dopamine-beta-hydroxylase and chromogranin-A, which are coreleased with NE by sympathetic nerve endings, were also measured. Plasma NE was higher in the hypothyroid (2.37 +/- 0.24 nmol/L) than in the euthyroid state (1.86 +/- 0.24 nmol/L; P less than 0.02) or in the controls (1.87 +/- 0.27 nmol/L). Plasma clearance of NE, however, was not affected after thyroid replacement (hypothyroid, 2.08 +/- 0.31 L/min; euthyroid, 1.94 +/- 0.21 L/min; controls, 1.86 +/- 0.15 L/min). There was no significant change in plasma dopamine-beta-hydroxylase (hypothyroid, 720 +/- 139 nmol/mL.h; euthyroid, 553 +/- 97 nmol/mL.h) or plasma chromogranin-A (hypothyroid, 48.9 +/- 7.1 ng/mL; euthyroid, 42.9 +/- 5.3 ng/mL) after thyroid replacement. We conclude that the increased plasma NE in hypothyroid patients is not due to a change in plasma clearance, but is more likely secondary to increased NE release.
authors.affiliation: Division of Cardiology, University of California, San Diego Medical Center 92103.
authors.forename: R
authors.initials: R
authors.lastname: Polikar
authors.forename: B
authors.initials: B
authors.lastname: Kennedy
authors.forename: M
authors.initials: M
authors.lastname: Ziegler
authors.forename: D T
authors.initials: DT
authors.lastname: O'Connor
authors.forename: J
authors.initials: J
authors.lastname: Smith
authors.forename: P
authors.initials: P
authors.lastname: Nicod
mesh_terms: D000328:Adult; D000368:Aged; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood*; D004299:Dopamine beta-Hydroxylase / Q000097:blood*; D005260:Female; D006207:Half-Life; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009411:Nerve Endings / Q000201:enzymology; D009419:Nerve Tissue Proteins / Q000097:blood*; D009638:Norepinephrine / Q000493:pharmacokinetics*; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000627:therapeutic use*
chemical_list: C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins; D009419:Nerve Tissue Proteins; D013972:Thyrotropin; D004299:Dopamine beta-Hydroxylase; D013974:Thyroxine; D009638:Norepinephrine